希瑪眼科(03309.HK)盈喜:預期2023年淨利6000萬港元至6500萬港元 同比扭虧為盈
格隆匯3月12日丨希瑪眼科(03309.HK)公吿,根據目前可得的截至2023年12月31日止年度未經審核財務資料,預期公司將實現轉虧為盈,使公司權益持有人應占利潤達6000萬港元至6500萬港元,而截至2022年12月31日止年度則錄得權益持有人應占虧損2190萬港元。
預期公司權益持有人應占利潤增加,主要是受到醫療服務產生的收益由2022財政年度的14.3億港元增加超過30%至2023財政年度的約19億港元所帶動,惟因銷售COVID-19相關醫療耗材產生的收益由2022財政年度的2.98億港元減少至2023財政年度的約1900萬港元而被部分抵銷。
集團繼續留意到中港兩地對集團眼科及牙科服務業務的需求持續,加上香港與深圳重新通關,於2023財政年度,集團於深圳以"深圳愛康健"品牌經營的牙科業務錄得收益顯著增長,並轉虧為盈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.